Fulgent Genetics (FLGT) EPS (Weighted Average and Diluted) (2016 - 2026)

Fulgent Genetics has disclosed EPS (Weighted Average and Diluted) across 11 years of filings, most recently posting -$0.8 for Q1 2026.

• EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.8, down 116.22% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.39 (down 79.7% YoY), and the FY2025 annual result was -$1.97, down 39.72% from the prior year.
• EPS (Weighted Average and Diluted) came in at -$0.8 for Q1 2026 at Fulgent Genetics, down from -$0.76 in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $4.93 in Q1 2022 to a low of -$4.3 in Q4 2023.
• The 5-year median for EPS (Weighted Average and Diluted) is -$0.44 (2023), against an average of -$0.31.
• Across the five-year window, EPS (Weighted Average and Diluted) plunged 833.33% in 2023 and soared 95.58% in 2024, its largest moves.
• Fulgent Genetics' EPS (Weighted Average and Diluted) stood at -$0.8 in 2022, then sank by 437.5% to -$4.3 in 2023, then surged by 95.58% to -$0.19 in 2024, then tumbled by 300.0% to -$0.76 in 2025, then retreated by 5.26% to -$0.8 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at -$0.8 (Q1 2026), -$0.76 (Q4 2025), and -$0.21 (Q3 2025), per Business Quant data.